Jun 26, 2026 08:30AM
Jun 26, 2026 08:30AM
Jun 15, 2026 08:30AM
May 13, 2026 04:02PM
May 11, 2026 04:02PM
Apr 16, 2026 08:50AM
Apr 16, 2026 08:45AM CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
Mar 31, 2026 04:02PM
Mar 26, 2026 08:45AM
Mar 21, 2026 03:23AM
Feb 17, 2026 08:45AM
Jan 27, 2026 09:02AM
Jan 27, 2026 09:00AM
Dec 29, 2025 05:11AM Omeros reschedules YARTEMLEA approval conference call to January 7
Dec 26, 2025 06:36PM
Dec 24, 2025 10:40AM
Dec 24, 2025 09:00AM
Dec 24, 2025 09:00AM
Dec 1, 2025 08:30AM
Dec 1, 2025 08:30AM
Nov 13, 2025 04:11PM Omeros Corporation Reports Third Quarter 2025 Financial Results
Nov 11, 2025 08:30AM
Oct 16, 2025 08:33AM
Oct 16, 2025 08:30AM
Oct 15, 2025 08:30AM
Sep 2, 2025 08:45AM
Sep 2, 2025 08:45AM
Aug 14, 2025 04:02PM Omeros Corporation Reports Second Quarter 2025 Financial Results
Aug 11, 2025 04:02PM
Jul 25, 2025 08:00AM
Jul 25, 2025 08:00AM
Jun 27, 2025 08:31AM
Jun 27, 2025 08:30AM
Jun 24, 2025 08:30AM
May 15, 2025 04:05PM Omeros Corporation Reports First Quarter 2025 Financial Results
May 12, 2025 05:05PM
May 12, 2025 08:41AM
May 12, 2025 08:41AM
May 6, 2025 09:16AM
May 6, 2025 09:16AM
Apr 10, 2025 09:10AM
Apr 10, 2025 09:10AM Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
Apr 8, 2025 09:00AM
Mar 31, 2025 04:02PM
Mar 26, 2025 09:15AM
Mar 21, 2025 09:15AM
Mar 21, 2025 09:15AM
Mar 13, 2025 09:00AM
Feb 20, 2025 09:11AM Omeros (OMER) Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
Feb 20, 2025 09:10AM

325,460 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All